Clinical Trial Update: Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Durvalumab (MEDI4736) and Tremelimumab with gemcitabine/cisplatin in chemotherapy-naïve biliary tract cancer (active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Biliary Tract Neoplasms

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)
• gemcitabine/cisplatin

Snippet

Sponsor: Seoul National University Hospital | Conditions: Biliary Tract Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING